KR102934264B1 - Sfrp2 길항제를 포함하는 조성물 및 방법 - Google Patents

Sfrp2 길항제를 포함하는 조성물 및 방법

Info

Publication number
KR102934264B1
KR102934264B1 KR1020237022926A KR20237022926A KR102934264B1 KR 102934264 B1 KR102934264 B1 KR 102934264B1 KR 1020237022926 A KR1020237022926 A KR 1020237022926A KR 20237022926 A KR20237022926 A KR 20237022926A KR 102934264 B1 KR102934264 B1 KR 102934264B1
Authority
KR
South Korea
Prior art keywords
antigen
antibody
sfrp2
binding fragment
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237022926A
Other languages
English (en)
Korean (ko)
Other versions
KR20230118904A (ko
Inventor
낸시 데모어
캠 패터슨
Original Assignee
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 filed Critical 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐
Publication of KR20230118904A publication Critical patent/KR20230118904A/ko
Application granted granted Critical
Publication of KR102934264B1 publication Critical patent/KR102934264B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237022926A 2020-12-11 2021-12-10 Sfrp2 길항제를 포함하는 조성물 및 방법 Active KR102934264B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063124345P 2020-12-11 2020-12-11
US63/124,345 2020-12-11
PCT/US2021/062854 WO2022125927A1 (en) 2020-12-11 2021-12-10 Compositions and methods comprising sfrp2 antagonists

Publications (2)

Publication Number Publication Date
KR20230118904A KR20230118904A (ko) 2023-08-14
KR102934264B1 true KR102934264B1 (ko) 2026-03-05

Family

ID=81974701

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237022926A Active KR102934264B1 (ko) 2020-12-11 2021-12-10 Sfrp2 길항제를 포함하는 조성물 및 방법

Country Status (10)

Country Link
US (2) US11873333B2 (https=)
EP (1) EP4259203A4 (https=)
JP (1) JP7747350B2 (https=)
KR (1) KR102934264B1 (https=)
CN (1) CN116744970A (https=)
AU (1) AU2021396381A1 (https=)
CA (1) CA3201893A1 (https=)
IL (1) IL303600A (https=)
MX (1) MX2023006777A (https=)
WO (1) WO2022125927A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102934264B1 (ko) 2020-12-11 2026-03-05 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Sfrp2 길항제를 포함하는 조성물 및 방법
WO2025076318A1 (en) * 2023-10-06 2025-04-10 Musc Foundation For Research Development Compositions for modulating the kras pathway and methods of use thereof
CN117756910A (zh) * 2023-12-22 2024-03-26 首都医科大学附属北京口腔医院 Sfrp2功能多肽及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015038882A1 (en) * 2013-09-13 2015-03-19 The University Of North Carolina At Chapel Hill Methods and compositions for tumor vasculature imaging and targeted therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
JP2011523551A (ja) 2008-05-15 2011-08-18 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 血管形成の調節の新規ターゲット
WO2011119524A1 (en) 2010-03-22 2011-09-29 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR102934264B1 (ko) 2020-12-11 2026-03-05 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Sfrp2 길항제를 포함하는 조성물 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015038882A1 (en) * 2013-09-13 2015-03-19 The University Of North Carolina At Chapel Hill Methods and compositions for tumor vasculature imaging and targeted therapy

Also Published As

Publication number Publication date
KR20230118904A (ko) 2023-08-14
US12258388B2 (en) 2025-03-25
US11873333B2 (en) 2024-01-16
US20220204598A1 (en) 2022-06-30
IL303600A (en) 2023-08-01
WO2022125927A1 (en) 2022-06-16
CA3201893A1 (en) 2022-06-16
EP4259203A1 (en) 2023-10-18
EP4259203A4 (en) 2024-12-18
JP2023553938A (ja) 2023-12-26
JP7747350B2 (ja) 2025-10-01
US20240190949A1 (en) 2024-06-13
AU2021396381A1 (en) 2023-07-06
CN116744970A (zh) 2023-09-12
MX2023006777A (es) 2023-08-17

Similar Documents

Publication Publication Date Title
KR102761792B1 (ko) B7-h4 항체 및 그의 사용 방법
CN111433223B (zh) 抗甲状腺素运载蛋白单克隆抗体的冻干制剂
KR101320198B1 (ko) 신생물의 치료를 위한 조성물 및 방법
DK2646470T3 (en) ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER
KR102934264B1 (ko) Sfrp2 길항제를 포함하는 조성물 및 방법
KR102478986B1 (ko) 암 치료용 항-ck8 항체
KR20140127875A (ko) 인테그린 αvβ6에 대한 항체 및 암을 치료하기 위한 그의 용도
CN113874081A (zh) 高-亲和力抗-mertk抗体及其用途
CN113166242B (zh) 用于癌症的组合疗法
KR102863169B1 (ko) B7-h4 항체 투약 섭생법
KR20200123170A (ko) B7-h4 항체 제형
KR20200040881A (ko) 항-pacap 항체
CN112368020A (zh) 抗pd-1抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法
KR20090067214A (ko) 순차적 병용 요법
CN112175087A (zh) 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
KR20230109854A (ko) 항-vegfr2(kdr) 개량 항체를 포함하는 융합단백질 및 이의 용도
KR20230109853A (ko) 항-vegfr2(kdr) 개량 항체를 포함하는 융합단백질 및 이의 용도
HK40036127B (zh) B7-h4抗体给药方案
HK40057716B (zh) 用於癌症的组合疗法
HK40063648A (en) High-affinity anti-mertk antibodies and uses thereof
HK40057716A (en) Combination therapy for cancer
HK40068969A (en) Treatment with site specific her2 antibody-drug conjugates
HK40036127A (en) B7-h4 antibody dosing regimens
EA043376B1 (ru) Составы антитела b7-h4
AU2014201911A1 (en) Compositions and methods for treating a neoplasm

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)